2023-05-15 17:20:16 ET
- InMed Pharmaceuticals press release ( NASDAQ: INM ): Q1 GAAP EPS of -$0.60.
- Revenue of $1.03M (+232.3% Y/Y).
For further details see:
InMed Pharmaceuticals GAAP EPS of -$0.60, revenue of $1.03M2023-05-15 17:20:16 ET
For further details see:
InMed Pharmaceuticals GAAP EPS of -$0.60, revenue of $1.03MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
Market:
InMed Pharmaceuticals Inc. Website:
InMed (NASDAQ: INM) is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Deg...
INM is advancing INM-089 targeting age-related macular degeneration and INM-901 targeting Alzheimer’s disease The company recently posted positive results for INM-089 demonstrating significant functional and pathological improvements in an AMD disease model Recent preclinical data for ...